Article Figures & Data
Figures
- FIGURE 1.
Baseline 68Ga-DOTATOC PET (left), CT (middle), and PET/CT (right) images of 61-y-old patient presenting with typical retractile MM surrounded by linear bands radiating into mesenteric fat (arrows) that were intensely hypermetabolic (Krenning score 4).
- FIGURE 2.
Patients’ estimated MM-related PFS (A) and non–MM-related PFS (B) since first dose of PRRT.
Tables
Characteristic Data Women 24 (46) Age (y) 70 (47–89) NET primary location Ileum 38 (73) Jejunum 6 (12) Not available 8 (15) WHO classification NET-G1 25 (48) NET-G2 22 (42) Unknown 5 (10) Ki-67 (%) in 44 patients 2.5 (1–16) Non-MM metastatic sites 0 3 (5) 1 17 (33) 2 16 (31) >2 16 (31) Location of metastatic sites Liver 45 (87) Distant lymph node 19 (37) Peritoneum 17 (33) Bone 14 (27) Other* 8 (15) Treatment received before PRRT Primary tumor resection 24 (46) Liver surgery 5 (10) Liver embolization 16 (31) Somatostatin analogs 47 (90) Targeted therapy with everolimus 10 (19) Chemotherapy 8 (15) ECOG performance status 0–1 50 (96) ≥2 2 (4) Clinical CS 39 (75) Carcinoid heart disease 7 (13) MM-related symptoms No symptoms on MM 26 (50) Abdominal pain 20 (38) Diarrhea 14 (27) Occlusive syndrome 8 (15) Mesenteric ischemia symptoms 5 (10) Constipation 3 (6) Vomiting 1 (2) MM uptake on SRI Krenning 2 or equivalent for PET 1 (2) Krenning 3 or equivalent for PET 4 (8) Krenning 4 or equivalent for PET 47 (90) CgA > 2 ULN 15 (29) MM RECIST progression before PRRT 20 (38) ↵* Other metastatic sites were ovary (n = 3), pancreas (n = 1), breast (n = 1), lung (n = 1), pericardium (n = 2), testis (n = 1), and muscle (n = 1).
WHO = World Health Organization; ECOG = Eastern Cooperative Oncology Group; SRI = somatostatin receptor imaging; ULN = upper limit of normal.
Categoric data are number and percentage; continuous data are median and range.
Characteristic Data Cycles <4 9 (17) 4 43 (83) Dose Full 49 (94) Reduced 3 (6) MM best morphologic response ORR 2 (4) Stable disease 50 (96) Non-MM best morphologic response ORR 4 (8) Stable disease 44 (90) Progressive disease 1 (2) MM best metabolic response ORR 0 (0) Stable disease 52 (100) Non-MM best metabolic response ORR 6 (12) Stable disease 43 (88) MM-related symptom clinical response Complete 3/26 (11) Partial 9/26 (35) Stability 14/26 (54) Progression 0/26 (0) CS clinical response Complete or partial 18 (46) Stability 19 (49) Progression 0 (0) Not available 2 (5) MM-related symptom long-term clinical response Complete 3 (11) Partial 8 (31) Stability 8 (31) Progression 3 (11) Missing data 4 (16) MM-related PFS (mo) Not reached Non-MM PFS (mo) 50.3 (38.2–61.7) Overall survival (mo) 55.0 (39.5–80.8) Categoric data are number or number per subpopulation, with percentage in parentheses. Continuous data are median, with 95% CI range in parentheses.
Characteristic Data Reason for early discontinuation of PRRT General health deterioration 2 (4) Toxicity 4 (8) Cholestasis 1 (2) Cytopenia 1 (2) Renal insufficiency 2 (4) Unknown 3 (6) Occurrence of gastrointestinal complications during PRRT 4* (8) Bowel obstruction 1 (2) Abdominal pain 2 (4) Diarrhea because of mesenteric ischemia 1 (2) Emesis 1 (2) Patients receiving short course of corticosteroid therapy 2 (4) Occurrence of long-term gastrointestinal complications 6* (12) Bowel obstruction 3 (6) Abdominal pain 3 (6) Constipation 2 (4) Perforation 1 (2) Mesenteric ischemia 1 (2) Cause of death in affected patients MM-related 2 (4) Occlusive syndrome with digestive perforation 1 (2) Missing data 1 (2) NET-related but non–MM-related 7 (13) Altered general condition with cachexia 4 (8) Missing data 3 (6) Non–NET-related 3 (6) Unknown 2 (4) ↵* One patient presented with both gastrointestinal complications during PRRT and long-term gastrointestinal complications.
Data are number and percentage.
Supplemental Data
Files in this Data Supplement:
